High incidence of antibiotic resistance among bacteria in 4 intensive care units at a university hospital in Sweden

Scandinavian Journal of Infectious Diseases

Volumn 29, Issue 6, 1997, Pages 607-614

  Hanberger, Hakan ^a   Hoffmann, Mikael ^a   Lindgren, Sune ^a   Nilsson, Lennart E ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMPICILLIN; ANTIBIOTIC AGENT; CEFOTAXIME; CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; COAGULASE NEGATIVE STAPHYLOCOCCUS; DRUG USE; ENTEROBACTER; ENTEROCOCCUS FAECALIS; GRAM NEGATIVE BACTERIUM; HOSPITAL PATIENT; HUMAN; INFECTION CONTROL; INTENSIVE CARE; PENICILLIN RESISTANCE; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; SWEDEN; TREATMENT PLANNING; UNIVERSITY HOSPITAL;

EID: 0031432432     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365549709035904     Document Type: Article

References (28)

1. Trilla A. Epidemiology of nosocomial infections in adult intensive care units. Intensive Care Med 1994; 20 (Suppl): S1-4.
2. Widmer AF. Infection control and prevention strategies in the ICU. Intensive Care Med 1994; 20S: 7-11.
3. Farr BM. Infection control in intensive care units: modern problems, modern solutions. Curr Opin Infect Dis 1993; 6: 520-525.
4. Jumaa P, Chattopadhayay B. Outbreak of gentamicin, ciprofloxacin-resistant Pseudomonas aeruginosa in an intensive care unit, traced to contaminated quivers. J Hosp Infect 1994; 28: 209-218.
5. Lingnau W, Allerberger F. Control of an outbreak of methicillin-resistant Staphylococcus aureus (MRSA) by hygienic measures in a general intensive care unit. Infection 1994; 22 (Suppl 2): S135-139.
6. Vincent JL, Bihari DJ, Suter PM, Bruining HA. White D, Nicolas-Chanoin M-H, Wolff M, Spencer RC, Hemmer M, for the EPIC International Advisory Committee. The prevalence of nosocomial infection in intensive care units in Europe: results of the European prevalence of infection in intensive care (EPIC) study. JAMA 1995; 274: 639-644.
7. Cunha BA. Intensive care not intensive antibiotics. Heart Lung 1994; 23: 361-362.
8. Kollef MH. Antibiotic use and antibiotic resistance in the intensive care unit: are we curing or creating disease? Heart Lung 1994; 23: 363-367.
9. Dornbusch K, Bengtsson S, Brorsson JE, Fritz H, Henning C, Kronwall G, Larsson D, Malmborg A-S, Thore M. Tärnsik A, Walder M. Susceptibility to betalactam antibiotics and gentamicin of gram-negative bacilli isolated from hospitalized patients: a Swedish multicenter study. Scand J Infect Dis 1988: 20: 641-647.
10. Dornbusch K, European Study Group on Antibiotic Resistance. Resistance to b-lactam antibiotics and ciprofloxacin in gram-negative bacilli and staphylococci isolated from blood: a European collaborative study. J Antimicrob Chemother 1990; 26: 269-278.
11. Dornbusch K, King A, Phillips I, Legakis NJ. Antibiotic resistance levels in European blood and urine isolates. A collaborative study (Abstract 259). In Abstracts of the 7th European Congress of Clinical Microbiology and Infectious Diseases, Vienna. Austria. European Society of Clinical Microbiology and Infectious Diseases 1995; 50.
12. Olsson-Liljequist B, Burman LG. Susceptibility of Swedish blood isolates to piperacillin-tazobactam compared with other antibiotics in 1992. In: Einhorn J, Nord CE, Norrby R, eds. Recent advances in chemotherapy and bacterial infections. American Society for Microbiology 1994; 191.2.
13. Walder M, Karlsson E, Nilsson B. Sensitivity of 880 blood culture isolates to 24 antibiotics. Scand J Infect Dis 1994; 26: 67-75, 1994.
14. Hanberger H, Nilsson LE. High frequency of antibiotic resistance among Gram-negative isolates in intensive care units at ten Swedish hospitals. Clin Microbiol Infection 1997; 3: 208-215.
15. Björnerot L, Franklin A, Tysén E. Usage of antibacterial and antiparasitic drugs in animals in Sweden between 1988 and 1993. Vet Rec 1996; 139: 282-286.
16. Norrby R. Svensk antibiotikaförbrukning 1991-ett mindre hedrande rekord. Läkartidningen 1992; 89: 1757-1763.
17. Norrby R. Bruket av antibiotika sakta på väg nedåt. Fort-farande överanvänds flera preparat. Läkartidningen 1995; 92: 1893-1899.
18. Olsson-Liljequist B, Larsson P, Walder M, Miörner H. Antimicrobial susceptibility testing in Sweden III. Methodology for susceptibility testing. Scand J Infect Dis Suppl 1997; 105: 13-23.
19. WHO Collaborating Centre for Drug Statistics Methodology. Norsk Medisinaldepot (NMD), Oslo, Norway.
20. Quale J, Landman D, Atwood E, Kreiswirth B, Willey BM, Ditore V, Zaman M, Patel K, Saurina G, Huang W, Oydna E, Burney S. Experience with a hospital-wide outbreak of a vancomycin-resistant enterococci. Am J Infect Control 1996; 24: 372-379.
21. Bonten MJM, Hayden MK, Nathan C, van Voorhis J, Matushek M, Slaughter S, Rice T, Weinstein RA. Epidemiology of colonisation of patients and environment with vancomycinresistant enterococci. Lancet 1996; 348: 1615-1619.
22. Kern WV, Andriof E, Oethinger M, Kern P, Hacker J, Marre R. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 38; 681-687.
23. Kresken M, Hafner D, Mittermayer H, Verbist L, Bergogne-Berezin E, Giamarellou H, Esposito S, van Klingeren B, Kayser FH, Reeves DS, Wiedemann B and the study group "Bacterial Resistance" of the Paul-Ehrlich-Society for Chemotherapy e.V. Prevalence of fluoroquinolone resistance in Europe. Infection 1994; 22 (Suppl): 90-98.
24. Sanders CC. Cefepime: the next generation? Clin Infect Dis 1993; 17: 369-379.
25. Sirot D. Extended spectrum plasmid-mediated betalactamases. J Antimicrob Chemother 1995; 36 (Suppl A): S19-34.
26. Fung-Tomc JC, Gradelski E, Huczko E, Dougherty, Kessler RE, Bonner DP. Differences in the resistant variants of Enter-obacter cloacae selected by extended-spectrum cephalosporins. Antimicrob Agents Chemother 1996; 40: 1289-1293.
27. Chow J, Fine M, Shlaes D, Quinn JP, Hooper DC, Johnson MP, Ramphal R, Wagener MM, Miyashiro DK, Yu VL. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991; 115: 585-590.
28. Gould IM. Risk factors for acquisition of multiple drug-resistant gram-negative bacteria, Eur J Clin Microbiol Infect Dis 1994; 13 (Suppl I): S30-38.